Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 20/20 | 0.64 |
| ▸ | CHRNB4 | P30926 | 20/20 | 0.64 |
| ▸ | CHRNA3 | P32297 | 20/20 | 0.64 |
| ▸ | CHRNA4 | P43681 | 20/20 | 0.64 |
| ▸ | CHRNA7 | P36544 | 18/20 | 0.59 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25391666 | 1.00 | CHRNB2 (0.64) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL25372135 | 1.00 | CHRNB2 (0.64) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL2186724 | 1.00 | CHRNB2 (0.64) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL3792324 | 0.98 | CHRNB2 (0.61) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL29134669 | 0.93 | CHRNB2 (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL25370321 | 0.91 | CHRNB2 (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL6318814 | 0.89 | CHRNB2 (0.52) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL23189549 | 0.85 | CHRNA4 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL1935638 | 0.85 | CHRNA4 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL21143524 | 0.85 | CHRNA4 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120192324-A | Heterocyclic compound, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| WO-2023141570-A9 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4387603-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | Enanta Pharmaceuticals, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024121779-A1 | PAPAIN-LIKE PROTEASE (PLPRO) INHIBITORS | PFIZER INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174674-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | APPLIED PHARMACEUTICAL SCIENCE, INC. (CN) | 2024-05-30 | — | — | US | disclosed |
| US-20240174667-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| EP-3189038-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| US-20170029390-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2016-11-17 | — | — | US | disclosed |
| EP-3091008-A1 | KINASE INHIBITOR AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2016-11-09 | — | — | EP | disclosed |
| US-20160304516-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. | 2016-10-20 | — | — | US | disclosed |
| US-20160108046-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| WO-2016037005-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-10 | — | — | WO | disclosed |
| EP-2489663-A1 | Compounds as syk kinase inhibitors | Almirall, S.A. (ES) | 2012-08-22 | — | — | EP | disclosed |
| EP-1671972-A1 | Octahydropyrrolo[3,4-c]pyrrole derivatives | Pfizer Limited (GB) | 2006-06-21 | — | — | EP | disclosed |
| US-20060111416-A1 | Octahydropyrrolo[3,4-C]pyrrole derivatives | PFIZER INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | CHRNB2 4631/4885CHRNB4 4711/4885CHRNA3 4753/4885 |
| US-20170029390-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | CHRNB2 802/4885CHRNB4 678/4885CHRNA3 638/4885 |
| US-20060111416-A1 | Octahydropyrrolo[3,4-C]pyrrole derivatives | DPYD, PAH, DHPS | CHRNB2 3168/4885CHRNB4 2565/4885CHRNA3 1805/4885 |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | CDK4, CDK6, CDK3 | CHRNB2 4861/4885CHRNB4 4821/4885CHRNA3 4741/4885 |
| US-20160108046-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | CHRNB2 2163/4885CHRNB4 2395/4885CHRNA3 2187/4885 |
| US-11999730-B1 | AKT1 modulators | AKT1S1, AKT1, AKT2 | CHRNB2 4631/4885CHRNB4 4711/4885CHRNA3 4753/4885 |
| US-20160304516-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | CHRNB2 2163/4885CHRNB4 2395/4885CHRNA3 2187/4885 |
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HCRTR1, HCRTR2, CCKBR | CHRNB2 776/4885CHRNB4 722/4885CHRNA3 769/4885 |
| US-20240174674-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | RET, WEE1, JAK2 | CHRNB2 4465/4885CHRNB4 4441/4885CHRNA3 4638/4885 |
| US-20240174667-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | CHRNB2 4631/4885CHRNB4 4711/4885CHRNA3 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.